Neurogenic
Clinical-stage diagnostics company developing sensitive immunoassays to assist in the diagnosis of mental disorders
Company Overview
Snapshot
Founded in February 1995, Neurogenic operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on the development of sensitive immunoassays for mental disorder diagnosis. A key milestone for Neurogenic was the establishment of a deal with SYnAbs in March 2019 for schizophrenia detection.
Business overview
Neurogenic is a clinical-stage diagnostics company specializing in the development of sensitive immunoassays to aid in the diagnosis of mental disorders. The company's core technology involves an ELISA-based immunoassay designed to detect Platelet-Associated Antibodies (PAA) in the sera of adolescent and pediatric patients with early-onset schizophrenia. Neurogenic serves the healthcare industry, particularly providers and laboratories, operating within the Health Tech & Life Sciences sector, with a focus on medical devices and diagnostics.
Strategic signal
In March 2019, Neurogenic announced a deal with SYnAbs for schizophrenia detection. This collaboration is significant as it validates Neurogenic's diagnostic approach and accelerates the development of its immunoassay, signaling progress in bringing its diagnostic tools to market and addressing a critical need in mental health diagnostics.
Log in to access full profile ›Company Intelligence Q&A
- What is Neurogenic's primary focus?
- Neurogenic is a clinical-stage diagnostics company developing sensitive immunoassays to assist in the diagnosis of mental disorders.
- When was Neurogenic founded?
- Neurogenic was founded in February 1995.
- What is the company's main product?
- Neurogenic is developing the Schizophrenia ELISA Diagnostic Assistant (SEDA) Assay, an immunoassay designed to detect Platelet-Associated Antibodies (PAA) for schizophrenia diagnosis.
- What significant partnership did Neurogenic establish?
- In March 2019, Neurogenic established a deal with SYnAbs for schizophrenia detection, focusing on advancing its diagnostic solutions.
- What stage is Neurogenic currently in?
- Neurogenic is currently in the Pre-Funding stage and its product is in Clinical Trial.